Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand the Pepaxti label to include third-line treatment.</li><li>Given this will take at least one year, it will not impact the near-term commercialisation of Pepaxti.</li><li>It could increase the total addressable market long-term, however.</li></ul>

Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand the Pepaxti label to include third-line treatment.Given this will take at least one year, it will not impact the near-term commercialisation of Pepaxti.It could increase the total addressable market long-term, however.

Oncopeptides: Intends to File for Third Line